lipolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Mental health === Evidence suggests that mental health can be a significant facilitator for opioid use disorder. Given that opioids are prescribed for pain management, mental health disorders, such as depression, have been shown to increase use of opioids when treating conditions associated with chronic pain. Evidence has shown that individuals with mood and anxiety disorders have an increased likelihood of being prescribed opioids and continuing usage for lengthy periods of time, consequently increasing likelihood for dependence. As such, affected individuals have almost double the risk of using opioids for pain relief in the long-term. Additionally, mental health challenges associated with trauma, economic depression, social environments conducive to substance use and risk-taking behaviours have been shown to increase opioid misuse. Furthermore, mental health challenges associated with cardiovascular disease, sleep disorders, and HIV can cause opioid dependence and subsequent overdose. Notably, cyclic behaviours can be observed between mental illness and opioid use disorder where individuals with mental health diagnoses engage in opioid use which further perpetuates mental health challenges and increased drug usage.
=== Atherosclerosis === Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells, thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol is a major contributor to atherosclerosis.
=== Contact process === In 1831, British vinegar merchant Peregrine Phillips patented the contact process, which was a far more economical process for producing sulfur trioxide and concentrated sulfuric acid. Today, nearly all of the world's sulfuric acid is produced using this method. In the early to mid 19th century "vitriol" plants existed, among other places, in Prestonpans in Scotland, Shropshire and the Lagan Valley in County Antrim, Northern Ireland, where it was used as a bleach for linen. Early bleaching of linen was done using lactic acid from sour milk, but this was a slow process; the use of vitriol sped up the bleaching process.
Systematic botany is part of systematic biology, which is concerned with the range and diversity of organisms and their relationships, particularly as determined by their evolutionary history. It involves, or is related to, biological classification, scientific taxonomy and phylogenetics. Biological classification is the method by which botanists group organisms into categories such as genera or species. Biological classification is a form of scientific taxonomy. Modern taxonomy is rooted in the work of Carl Linnaeus, who grouped species according to shared physical characteristics. These groupings have since been revised to align better with the Darwinian principle of common descent – grouping organisms by ancestry rather than superficial characteristics. While scientists do not always agree on how to classify organisms, molecular phylogenetics, which uses DNA sequences as data, has driven many recent revisions along evolutionary lines and is likely to continue to do so. The dominant classification system is called Linnaean taxonomy. It includes ranks and binomial nomenclature. The nomenclature of botanical organisms is codified in the International Code of Nomenclature for algae, fungi, and plants (ICN) and administered by the International Botanical Congress. Kingdom Plantae belongs to Domain Eukaryota and is broken down recursively until each species is separately classified. The order is: Kingdom; Phylum (or Division); Class; Order; Family; Genus (plural genera); Species.
Sources: en.wikipedia.org
A research study in which the medical records of groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke and those who do not smoke) are compared for a particular outcome. Also called a historic cohort study. (NCI) Retrospective study
Initially, Owens believed the Wests had been sincere in their apologies and obliged, believing she had simply mistaken their earlier intentions. Rose joined her in the back seat, with the explanation she wanted a "girls' chat" as Fred drove. Shortly thereafter, Rose began to fondle Owens, as Fred questioned whether she had had sex with her boyfriend that evening. When Owens began to protest, Fred stopped the car, referred to Owens as a "bitch" and punched her into unconsciousness before he and Rose bound and gagged her with a scarf and duct tape. In her subsequent statement to police, Owens stated that, at Cromwell Street, she was given a drugged cup of tea to drink before being again gagged and subjected to a prolonged sexual assault from the Wests. When Owens screamed, Rose smothered her with a pillow, further restrained her about the neck and performed cunnilingus on her. Realising the gravity of her situation, Owens ceased resisting their sexual assaults. The following morning, having noted Owens' screaming when one of his children had knocked on the door of the room in which she was restrained, Fred threatened that he and his wife would keep her locked in the cellar and allow his "black friends" to abuse her, and that when they had finished he would bury her body beneath "the paving stones of Gloucester." Fred then claimed he had killed hundreds of young girls, adding that Owens had primarily been brought to the house for "Rose's pleasure." He and Rose then calmly asked Owens whether she would consider returning to work as their nanny.
=== Fossil record === The earliest widely accepted animal fossils are rather modern-looking cnidarians, possibly from around 580 million years ago, although fossils from the Doushantuo Formation can only be dated approximately. The identification of some of these as embryos of animals has been contested, but other fossils from these rocks strongly resemble tubes and other mineralized structures made by corals. Their presence implies that the cnidarian and bilaterian lineages had already diverged. Although the Ediacaran fossil Charnia used to be classified as a jellyfish or sea pen, more recent study of growth patterns in Charnia and modern cnidarians has cast doubt on this hypothesis, leaving the Canadian polyp Haootia and the British Auroralumina as the only recognized cnidarian body fossils from the Ediacaran. Auroralumina is the earliest known animal predator. Few fossils of cnidarians without mineralized skeletons are known from more recent rocks, except in Lagerstätten that preserved soft-bodied animals. A few mineralized fossils that resemble corals have been found in rocks from the Cambrian period, and corals diversified in the Early Ordovician. These corals, which were wiped out in the Permian–Triassic extinction event about 252 million years ago, did not dominate reef construction since sponges and algae also played a major part. During the Mesozoic era, rudist bivalves were the main reef-builders, but they were wiped out in the Cretaceous–Paleogene extinction event 66 million years ago, and since then the main reef-builders have been scleractinian corals.
Sources: en.wikipedia.org
There are two main application fields of FMO: biochemistry and molecular dynamics of chemical reactions in solution. In addition, there is an emerging field of inorganic applications. In 2005, an application of FMO to the calculation of the ground electronic state of photosynthetic protein with more than 20,000 atoms was distinguished with the best technical paper award at Supercomputing 2005. A number of applications of FMO to biochemical problems has been published, for instance, to Drug design, quantitative structure-activity relationship (QSAR) as well as the studies of excited states and chemical reactions of biological systems. The adaptive frozen orbital (AFO) treatment of the detached bonds was developed for FMO, making it possible to study solids, surfaces and nano systems, such as silicon nanowires. FMO-TDDFT was applied to the excited states of molecular crystals (quinacridone). Among inorganic systems, silica-related materials (zeolites, mesoporous nanoparticles and silica surfaces) were studied with FMO, as well as ionic liquids and boron nitride ribbons. There are other applications of FMO.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{232}_{90}Th->[\alpha ][1.40\times 10^{10}\ {\ce {y}}]{^{228}_{88}Ra}->[\beta ^{-}][5.75\ {\ce {y}}]{^{228}_{89}Ac}->[\beta ^{-}][6.15\ {\ce {h}}]{^{228}_{90}Th}->[\alpha ][1.9125\ {\ce {y}}]{^{224}_{88}Ra}->[\alpha ][3.632\ {\ce {d}}]{^{220}_{86}Rn}}}\\{\ce {^{220}_{86}Rn->[\alpha ][55.6\ {\ce {s}}]{^{216}_{84}Po}->[\alpha ][144.0\ {\ce {m}}s]{^{212}_{82}Pb}->[\beta ^{-}][10.627\ {\ce {h}}]{^{212}_{83}Bi}}}{\begin{Bmatrix}{\ce {->[64.06\%\beta ^{-}][60.55\ {\ce {min}}]{^{212}_{84}Po}->[\alpha ][294.4\ {\ce {ns}}]}}\\{\ce {->[35.94\%\alpha ][60.55\ {\ce {min}}]{^{208}_{81}Tl}->[\beta ^{-}][3.053\ {\ce {min}}]}}\end{Bmatrix}}{\ce {^{208}_{82}Pb}}\end{array}}}
== Industrial uses == Pentanes are some of the primary blowing agents used in the production of polystyrene foam and other foams. Usually, a mixture of n-, i-, and increasingly cyclopentane is used for this purpose. Acid-catalyzed isomerization gives isopentane, which is used in producing high-octane fuels. Because of their low boiling points, low cost, and relative safety, pentanes are used as a working medium in geothermal power stations and organic Rankine cycles. It is also used in some blended refrigerants. Pentanes are solvents in many ordinary products, e.g. in some pesticides.
=== Sixth Form === Woodhouse Grammar School was later reconstituted as Woodhouse Sixth Form College. There were plans to merge the school with Friern Barnet County Secondary School in 1971, but these were blocked by local MP Margaret Thatcher. Thatcher gave a speech at the college in May 1983. In January 2021 Woodhouse College converted to academy status and is now part of the Frontier Learning Trust.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.